Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib

Pharmacologic inhibitors of cyclin-dependent kinases 4 and 6 (CDK4 and 6) are approved for the treatment of subsets of patients with hormone receptor positive (HR+) breast cancer (BC). In metastatic disease, strategies involving endocrine therapy combined with CDK4 and 6 inhibitors (CDK4 and 6i) imp...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The oncologist (Dayton, Ohio) Ohio), 2022-10, Vol.27 (10), p.811-821
Hauptverfasser:	Wander, Seth A, O'Brien, Neil, Litchfield, Lacey M, O'Dea, Declan, Morato Guimaraes, Claudia, Slamon, Dennis J, Goel, Shom
Format:	Artikel
Sprache:	eng
Schlagworte:	Academia-Pharma Intersect Aminopyridines - pharmacology Aminopyridines - therapeutic use Benzimidazoles Breast cancer Breast Neoplasms - pathology Care and treatment Cyclin-Dependent Kinase 4 Cyclin-Dependent Kinase 6 Cyclins Estrogens Female Health aspects Humans Mitogens - therapeutic use Patient outcomes Protein Kinase Inhibitors - pharmacology Protein Kinase Inhibitors - therapeutic use Tumor Suppressor Proteins
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!